PT  - JOURNAL ARTICLE
AU  - Davide Chiasserini
AU  - Irene Bijnsdorp
AU  - Giovanni Bellomo
AU  - Pier Luigi Orvietani
AU  - Sander R. Piersma
AU  - Thang V. Pham
AU  - Lucilla Parnetti
AU  - Connie R. Jiménez
TI  - Proteomic analysis of extracellular vesicles in cerebrospinal fluid of patients with Alzheimer’s disease
AID  - 10.1101/2020.02.22.20026609
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.22.20026609
4099  - http://medrxiv.org/content/early/2020/02/25/2020.02.22.20026609.short
4100  - http://medrxiv.org/content/early/2020/02/25/2020.02.22.20026609.full
AB  - Cerebrospinal fluid (CSF) contains different types of extracellular vesicles (EVs) with undisclosed biomarker potential for neurodegenerative diseases. The aims of the present study were: i) to compare the proteome EVs isolated using different ultracentrifugation speed ii) to preliminary explore the EVs proteome in a common neurodegenerative disorder, Alzheimer’s disease (AD) compared to neurological controls. CSF samples from control subjects and AD patients were pooled separately (15 mL) and subjected to ultracentrifugation (UC) at different speeds (20,000g and 100,000g) to isolate separate EV fractions (P20 and P100). The proteome was analysed using high-resolution mass spectrometry (LC-MS/MS) and comparisons were made using bioinformatic analysis. EVs isolated at 100,000g (P100) had a proteome consistent with vesicles secreted via an ESCRT-dependent mechanism, being highly enriched in alix (PDCD6IP), syntenin-1 (SDCBP) and TSG101. EVs isolated at 20,000g were substantially different, showing enrichment in cytoskeletal and cell adhesion molecules. The pools from patients diagnosed with AD showed a distinct protein profile of CSF EVs, with increased levels of ADAM10, SPON1, CH3IL1 and MDK in the P100 fraction. CSF EV offer a new potential biosource of protein markers for AD detection and a complementary framework to the analysis of whole biological fluids for biomarker discovery.Competing Interest StatementProf. Parnetti served as Member of Advisory Boards for Fujirebio, IBL, Roche and Merck. The other authors declare no competing financial interest.Funding StatementVUmc-Cancer Center Amsterdam is acknowledged for the proteomics infrastructure.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request